FDA Approves New Kind of Drug for Schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and. Drug Administration. Cobenfy (xanomeline/trospium chloride) could bring patients what they've long hoped for: A means of easing the hallucinations and "voices" that disrupt their lives without the weight gain and sluggishness of current dopamine-focused drugs.
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...
5h
Wells Fargo analyst Mohit Bansal has maintained their neutral stance on BMY stock, giving a Hold rating on September 23. Mohit Bansal has ...
Importantly, Bristol-Myers Squibb Company (NYSE:BMY) does carry debt. But should shareholders be worried about its use of debt? Debt assists a business until the business has trouble paying it ...
Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...
Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...
Shares of Bristol Myers Squibb Co. BMY slipped 1.45% to $49.02 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to ...
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback